Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Marchetti

Showing results (371-380 of 415) with videos related to

Pageof 42
Sort By:
Therapeutic Advances in Medical Oncology|February 4, 2020
Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a <i>post hoc</i> analysis from the adjuvant TOSCA trialSandro Barni, Gerardo Rosati, Sara Lonardi, et al.
Cancer Biology & Therapy|January 17, 2018
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumabLaura Pizzuti, Domenico Sergi, Isabella Sperduti, et al.
Frontiers in Immunology|April 28, 2017
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup StudyPaola Queirolo, Beatrice Dozin, Anna Morabito, et al.
Frontiers in Immunology|March 14, 2018
Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup StudyPaola Queirolo, Beatrice Dozin, Anna Morabito, et al.
International Journal of Medical Sciences|April 16, 2021
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS TrialEriseld Krasniqi, Laura Pizzuti, Maria Rosaria Valerio, et al.
NPJ Breast Cancer|July 17, 2024
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY studySimone Scagnoli, Simona Pisegna, Angela Toss, et al.
Clinical Lung Cancer|March 20, 2019
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC PatientsAlessio Cortellini, Rita Chiari, Biagio Ricciuti, et al.
Oncotarget|February 25, 2016
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcomePatrizia Vici, Laura Pizzuti, Isabella Sperduti, et al.
European Journal of Cancer (Oxford, England : 1990)|February 29, 2020
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse eventsAlessio Cortellini, Melissa Bersanelli, Daniele Santini, et al.
La Radiologia Medica|July 7, 2026
Request and reporting models for computed tomography in the multidisciplinary management of cancer patients: consensus between the Italian Society of Medical and Interventional Radiology (SIRM) and the Italian Society of Medical Oncology (AIOM)Vincenza Granata, Alessandro Serafini, Roberta Fusco, et al.
Pageof 42

Showing results (371-380 of 415) with videos related to

Sort By:
Pageof 42
Therapeutic Advances in Medical Oncology|February 4, 2020
Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a <i>post hoc</i> analysis from the adjuvant TOSCA trialSandro Barni, Gerardo Rosati, Sara Lonardi, et al.
Cancer Biology & Therapy|January 17, 2018
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumabLaura Pizzuti, Domenico Sergi, Isabella Sperduti, et al.
Frontiers in Immunology|April 28, 2017
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup StudyPaola Queirolo, Beatrice Dozin, Anna Morabito, et al.
Frontiers in Immunology|March 14, 2018
Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup StudyPaola Queirolo, Beatrice Dozin, Anna Morabito, et al.
International Journal of Medical Sciences|April 16, 2021
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS TrialEriseld Krasniqi, Laura Pizzuti, Maria Rosaria Valerio, et al.
NPJ Breast Cancer|July 17, 2024
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY studySimone Scagnoli, Simona Pisegna, Angela Toss, et al.
Clinical Lung Cancer|March 20, 2019
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC PatientsAlessio Cortellini, Rita Chiari, Biagio Ricciuti, et al.
Oncotarget|February 25, 2016
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcomePatrizia Vici, Laura Pizzuti, Isabella Sperduti, et al.
European Journal of Cancer (Oxford, England : 1990)|February 29, 2020
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse eventsAlessio Cortellini, Melissa Bersanelli, Daniele Santini, et al.
La Radiologia Medica|July 7, 2026
Request and reporting models for computed tomography in the multidisciplinary management of cancer patients: consensus between the Italian Society of Medical and Interventional Radiology (SIRM) and the Italian Society of Medical Oncology (AIOM)Vincenza Granata, Alessandro Serafini, Roberta Fusco, et al.
Pageof 42